Maha Othman (@MahaOthman8) on 10-Year Anniversary of the @canvector Research Network! @DebSiegal | @queensu https://t.co/6eMUricsdd #CanVECTOR #GynecologicalTumours #Health #Hematology #Hemostasis #HemostasisToday #Medicine #Thrombosis #MedEd #MedX

New insights from Dr Durr at the @canvector 2025 meeting! Despite standard LMWH thromboprophylaxis, fewer than half of ICU patients reach target anti-Xa levels. 👉 Sub-prophylactic anti-Xa levels = ~3× higher VTE risk We need to rethink “standard” dosing in ICU

Are you a #Thrombosis nerd? Do you love anticoagulation questions that no one else seems to care about, but everyone calls you for help? You’re among friends at @ThrombosisCan Join us at our Annual Conference + Morning Report for challenging cases! 👉 https://t.co/Octv0s0rsE

We’re so proud to see our Patient Partner, Carol West, featured on the @isth Pulse Podcast for #WorldThrombosisDay! 🎙️💙 Carol shares her journey and the vital role of patient voices in thrombosis research. A must-listen 👉 https://t.co/KQLQoxJ3Iu #WTDay25 #PatientsAsPartners

🚨Collab alert! @thrombosisday teamed up with the ISTH Pulse Podcast for an episode with Carol, WTD patient ambassador of the year! She shares her journey through multiple clots, her role as a co-lead in @canvector & more: https://t.co/ISB3FDpdB1

D-dimer: more false positives with age. But does an age-adjusted cutoff finally solve the problem? See what the ADJUST-DVT study found when we hear from Dr Gregoire Le Gal at https://t.co/wRJJk4VKF2 on October 25 in Toronto. Register today. Don't miss out.

🇨🇦 Survey from @ThrombosisCan in @ThiemeMedical: > 50% of Canadians with cancer have little or no awareness of cancer-associated thrombosis (CAT) — a leading cause of death in cancer. 📊 Only 27% recalled education on CAT risks; most want more info! 👉 https://t.co/chhUNcLFbD

🧠 Diagnosing recurrent VTE is challenging. PREDICTORS study (n=723) showed that existing clinical decision rules (CDRs) identify patients at higher risk and RO recurrence without imaging in ~15% 📊 In low/moderate-risk PE with negative D-dimer: 🟢 0/82 recurrent VTE (0%; 95% CI

Have you downloaded the latest episode of CLOT Conversations yet? Learn what the contestants of the @INVENT_VTE "Dragon's Den" pitched to get support for their studies, like Dr Francis Couturaud (@fcouturaud) with his ETHER Study. Access it here: https://t.co/u4B92PYBVb or on

Thanks for the shout out Patricia. As the incoming chair for this SSC, now working with colleagues to structure our projects agenda and priorities for the next few years we welcome ideas, new project leads and collaborations.

[1/2] Congratulations to Dr. Maha Othman who received a Minister’s Award of Excellence in the #EverydayHeroes category.

🩸 WaVE Study Alert! In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective. 🔹 Anti-Xa levels aligned with non-obese patients 🔹 Higher levels seen in those with bleeding Important data to guide dosing in CAT & obesity.

Tissue Factor as a Prognostic Marker in Acute PE: Time for Clinical Trials? @MarcCarrier1 https://t.co/KzpRyIVpBB #AcutePE #Hematology #HemostasisToday #TissueFactor #Medicine #Health #MedEd #MedX

Marc Carrier(@MarcCarrier1) Highlights Risk Factors For Recurrent VTE And Bleeding in CAT https://t.co/YVT05GhzbF #Cancer #Hematology #Hemostasis #MedEd #MedX #HemostasisToday #ISTH2025 #VTE #Medicine #Health

🧠 #ISTH2025 SCC survey on stroke in cancer patients: 1️⃣ Physicians choose reperfusion strategies differently for patients with vs. without cancer 2️⃣ Antiplatelets remain the most used for secondary prevention regardless of cancer 3️⃣ Major equipoise on workup post-stroke in

🩸 Important findings from Dr @IMYanXu at #ISTH2025: Black individuals on extended anticoagulation for secondary VTE prevention had higher rates of major bleeding, including ICH, than White individuals. 🔎 No difference in CRNMB. 📢 Calls for action to address racial

Come say hello to David Airdrie, our Executive Director at Thrombosis Canada, at Booth 623! 👋 Learn more about our clinical guides, patient resources, and upcoming education initiatives. 📍#ISTH2025 – We’re here to connect! @ThrombosisCan

🩸 Clots tend to come back at the same site as the index VTE! Among 708 patients with prior VTE, recurrences often occurred at the same site as the original event, especially ipsilateral DVTs. Familiar symptoms? Trust your clinical instincts. #ISTH2025 #VTE #DVT

📢 Practice-changing data from the Adjust-DVT study! ✅ Age-adjusted D-dimer safely rules out DVT in low/non-high pretest probability patients 📉 Reduces unnecessary ultrasounds 🔍 +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #LessIsMore

At #ISTH2025 ? Don’t miss Prof. Le Gal present on the network endorsed Adjust-#DVT study at 10:30 am ET in room 146 A-C. An incredible multi-national research achievement! #thrombosis #research